The effect of alendronate treatment on iPTH levels in elderlies with age-related osteoporosis

The effect of alendronate treatment on iPTH levels in elderlies with age-related osteoporosis: a clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241108063637N1

Enrollment

Registered

2024-12-11

Start date

2024-12-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis. Osteoporosis in other diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Intervention group: Only calcium will be given daily along with alendronate 70 mg weekly. After three months, calcium, phosphorus, VIT D, and iPTH will be checked a

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: Women over 65 years of age and men over 70 years of age who have indications of age-related osteoporosis.

Exclusion criteria

Exclusion criteria: Severe secondary osteoporosis (T Score = -4) Osteoporosis with fractures and any possible disease that leads to secondary osteoporosis Use of drugs that cause osteoporosis, such as long-term use of corticosteroids

Design outcomes

Primary

Measure	Time frame
Intact parathyroid hormone (iPTH). Timepoint: Before the start of the intervention and 3 months after the intervention. Method of measurement: To measure iPTH, a blood sample is taken from the patient. You must also observe fasting conditions for 8 to 12 hours.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Besharati Kiv

Zanjan University of Medical Sciences

besharati106@gmail.com+98 24 3377 0804

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026